*Onglyza fails to show cardiovascular benefit in study. *Positive results might have added $1 bln to peak sales. LONDON, June 19- AstraZeneca and Bristol-Myers Squibb's diabetes drug Onglyza failed to reduce heart risks in a large clinical study, disappointing investors who had thought it might demonstrate an edge over rivals.
Baxter International Inc. rose$. 11 or. 2 percent, to $70.84. Bristol-Myers Squibb Co. rose$. 28 or. 6 percent, to $46.72. Hospira rose$. 10 or. 3 percent, to $36.52.
Baxter International Inc. rose$. 39 or. 6 percent, to $70.99. Bristol-Myers Squibb Co. rose$. 14 or. 3 percent, to $46.95. Hospira rose$. 36 or 1.0 percent, to $36.60.
NEW YORK-- Shares of Codexis Inc. jumped Friday after the company said it reached an important milestone in development of detergent alcohols made from biomass. THE SPARK: Codexis and its partner Chemtex said they have scaled up production of CodeXol detergent alcohols.
Baxter International Inc. rose$. 08 or. 1 percent, to $70.83. Bristol-Myers Squibb Co. fell$. 23 or. 5 percent, to $46.94. Hospira fell$. 12 or. 3 percent, to $36.34.
June 13- Eli Lilly and Co. said on Thursday it halted a mid-stage study of an experimental Alzheimer's disease treatment due to potential liver toxicity, the latest setback in the quest to find a treatment that can slow or cure the memory-robbing condition.
Baxter International Inc. fell$. 01 or percent, to $69.74. Bristol-Myers Squibb Co. fell$. 09 or. 2 percent, to $46.48. Hospira fell$. 05 or. 1 percent, to $35.20.
Baxter International Inc. rose$. 15 or. 2 percent, to $69.92. Bristol-Myers Squibb Co. fell$. 17 or. 4 percent, to $47.12. Hospira fell$. 61 or 1.7 percent, to $35.47.
Baxter International Inc. rose$. 70 or 1.0 percent, to $70.22. Bristol-Myers Squibb Co. rose$. 23 or. 5 percent, to $47.23. Hospira rose$. 62 or 1.8 percent, to $35.65.
Baxter International Inc. fell$. 04 or. 1 percent, to $68.80. Bristol-Myers Squibb Co. rose$. 58 or 1.3 percent, to $46.75. Hospira rose$. 27 or. 8 percent, to $34.76.
They included drugs from Bristol-Myers Squibb and Merck& Co that shrank tumors in patients with advanced melanoma and lung cancer. Citigroup analysts expect such "immunotherapies" to cost around $110,000 in the United States for a year's worth of treatment and $80,000 in the rest of the world, generating sales of $35 billion a year in the next 10 years.
TOKYO, June 4- U.S. oil edged lower on Tuesday but held above $93 per barrel, as worries about slack demand weighed on prices after a late rebound the previous day on a slump in the dollar. *NYMEX crude for July delivery was down 27 cents at $93.18 a barrel by 2344 GMT, after settling up $1.48 at $93.45 on Monday.
NEW YORK, June 3- U.S. stocks rose on Monday, helped by weaker-than-expected factory activity that supported views the Federal Reserve will keep economic stimulus in place, while gains in Merck& Co lifted drug companies.
NEW YORK, June 3- U.S. stocks rose on Monday as weaker-than-expected factory activity last month supported views that the Federal Reserve will need to keep economic stimulus in place, while gains in Merck& Co's lifted drug companies. Intel Corp helped the Nasdaq turn positive in the final hour of trading, rising 3.9 percent to $25.23.
NEW YORK, June 3- Stocks and the U.S. dollar struggled on Monday in a seesaw session after data showed U.S. manufacturing activity contracted for the first time in six months, raising concerns about the health of the U.S. recovery. The Institute for Supply Management reported that its gauge for new orders slipped and said there was less demand for exports.
NEW YORK, June 3- The S&P 500 index was little changed on Monday as weaker-than-expected factory activity last month fed worries the economic recovery was struggling, while gains in Merck& Co's shares lifted the Dow and other drug companies.
NEW YORK, June 3- U.S. stocks were mostly lower in choppy trade on Monday as the latest data on manufacturing continued to paint a mixed picture on the strength of the economy. The S&P 500 fluctuated between losses and gains but the Dow managed to post a slight gain, boosted by a 5.3 percent jump in Merck& Co Inc..
*Dollar falls below 100 yen, lowest since early May. NEW YORK, June 3- Stocks and the dollar declined on Monday in volatile trading after a U.S. report on domestic manufacturing activity showed a contraction for the first time in six months, raising concerns about the health of the U.S. recovery.
The Fast Money traders share their final trades of the day.
Tuesday, 18 Jun 2013 | 5:00 PM ETAhead of the Fed meeting, the S&P 500 appears headed toward 1,687, StockMonster's Guy Adami says.
Tuesday, 18 Jun 2013 | 6:40 PM ETYou say the name of a stock, and Mad Money's Jim Cramer tells you whether to buy or sell.